ZFAS1 expression was significantly higher in ESCC tissues compared with the corresponding adjacent normal tissues.clinicopathological factors and ZFAS1 expression,can accurately predict the prognosis of lymph node-negative ESCC patients without preoperative chemoradiotherapy. ZFAS1 was found to act as a competing endogenous RNA (ceRNA) in liver cancer by binding to miR-150 and inhibiting the tumor suppressor function of miR-150. ZFAS1 promoted the increased expression of SP1 in ovarian cancer by competitive antagonism against miR-150 to enhance the ability of cell proliferation and chemotherapy resistance for ovarian cancer cells. ZFAS1 acts as an oncogene in colorectal cancer.ZFAS1 was found to promote gastric cancer cell proliferation by inhibiting KLF2 and NKD2 expression.